Hope for dravet families: phase 3 trial of zorevunersen launches
Disease control
Recruiting now
This study tests a new drug, zorevunersen, in 170 children aged 2 to 17 with Dravet syndrome, a severe form of epilepsy. The goal is to see if the drug can reduce seizure frequency and improve daily living skills compared to a sham procedure. Participants will be randomly assigne…
Phase: PHASE3 • Sponsor: Stoke Therapeutics, Inc • Aim: Disease control
Last updated May 11, 2026 20:51 UTC